



**British Society for
Paediatric Endocrinology
and Diabetes**

BSPED December 2021

The 48th BSPED 2021 Online Meeting

Thank you to those that attended the BSPED 2021 Online Meeting 24th – 26th November 2021. We thoroughly hope you enjoyed the conference, the scientific programme and networking with industry peers.

All session content is available on-demand for the next six months to registered delegates. Please click [here](#) to access the below:

- **Top scoring abstracts as oral communications and virtual posters**
- **A variety of diabetes and endocrine expert talks/symposia by several international and national speakers**
- **Personal Practice session**
- **Presentations from previous year's BSPED Award winners**
- **Plenary talk by the James M Tanner Award winner**
- **BSPED 2021 Awards Session**
- **Industry sponsored Satellite Symposia and Meet the Expert sessions**

Certificates of attendance were issued on Thursday 2nd December, if you have not yet received this, please email the team at bsped@endocrinology.org

Save the date!

Join us in person next year for the 49th Annual BSPED Meeting in Belfast 2nd – 4th November 2022.



News from the BSPED Office

ACCEA Awards 2022

In March 2021, the Department of Health and Social Care (DHSC) consulted on [reforms to the National Clinical Excellence Award scheme](#). DHSC is currently preparing the government response for publication.

The 2022 award round is expected to open for applications later in the year than usual.

We hope to give an update in early spring, including links to information on the new scheme, including what is required and when.

Timings for the 2022 awards round are not yet available.

For further information and updates, please refer to the [ACCEA website](#)



AGM minutes available

The 2020 annual general meeting of the British Society of Paediatric Endocrinology and Diabetes was held on 12 November 2020. Thank you to all of you who attended virtually. We heard a comprehensive round-up of developments from the Society and the field and minutes are now available in the [Members' Area of the BSPED website](#).

Food for thought: BMJ link – continuity of care in diabetes

Last year's debate on continuity of care at the BSPED annual conference was a hot topic. Dr Rachel Besser, consultant paediatric endocrinologist from Oxford, has written about her experience in this BMJ post.

[Practicing medicine in the virtual world—continuity of care is even more important - The BMJ](#)

Benefactor Resource Library

Head to the [BSPED Members' Area online](#) to find additional information, resources, promotional material and educational content from our benefactors in our Benefactor Resource Library.

All content is provided by our industry benefactors and any views expressed are not those of the BSPED.

More content is being added, so be sure to check back.



BSPED Byelaws – for information

The byelaws (or rules) of the BSPED have recently been reviewed and slightly updated by the Executive Committee. This was mainly to reflect the updated membership categories and the fact that all BSPED members will be asked to renew their membership within three months of the due date each year rather than six, to ensure membership records are up to date. Honorary members are now voting members and we have also made provision for virtual AGMs, in circumstances such as those we have experienced over the past year.

[The current byelaws can always be found on the BSPED website.](#)

Get all the latest endocrine news



Did you know that the BSPED website displays a regularly updated feed of endocrine and paediatric endocrine news from across the media? Visit the BSPED home page or our **[dedicated news page](#)** to stay up to date with new developments. News from the BSPED is also displayed.

Trainee Update

Diabetes & Endocrinology CSAC Meeting: January 2022

The next CSAC meeting has been rescheduled to January 2022. Please contact us with any queries or issues you would like us to raise with the CSAC. These can relate to SPIN Diabetes Training or GRID Endocrinology Training. Please email bspedtrainerep@gmail.com

VPET (Virtual Paediatric Endocrine Teaching): 14th January 2022

VPET now runs on the second Tuesday of every even month and second Friday of every odd month. If you would like to be added to the VPET mailing list or would like further information, please email vpet.trainees@gmail.com

PRETT-Y (Paediatric Regional Endocrinology Teaching and Training- Yorkshire) Study Day: 25th January 2022

The topic for the next PRETT-Y meeting is 'The Endocrine-Bone Interface', comprising sessions on skeletal dysplasia, the endocrine and bone approach to children with neuromuscular disorders, eating disorders for the endocrinologist, thyroid nodules and surgery.

If you would like to reserve a place or would like further information, please email elspethferguson@nhs.net

ACDC (Association of Children's Diabetes Clinicians) Meeting: 4th February 2022- postponed

This meeting has been moved from 4th February 2022 to Friday 6th May 2022 due to current circumstances with the Omicron variant.

Please visit <https://www.a-c-d-c.org/forthcoming-acdc-meetings/> for further information

Book your tickets here for the 16th ACDC Annual Conference which will be held in-person at Conference Aston in Birmingham:

<https://www.eventbrite.co.uk/e/16th-acdc-annual-conference-tickets-162895798719>

Awards, Achievements and Appointments

We would like to congratulate Dr Elspeth Ferguson on her appointment to Sheffield Children's Hospital as their newest Consultant Paediatric Endocrinologist. We wish her all the best in her new role.

BSPED Trainee Mailing List and Noticeboard

We send regular email updates on courses, job opportunities and information on training to trainees who are on our mailing list.

Updates are also posted on our online noticeboard, which is hosted on Trello.

Please email bspedtrainerep@gmail.com for further details of how to join or if you have feedback on any training issues.

Abiramy Fernando, Katherine Hawton & Rachel Boal

News from the Clinical Committee

BSPED Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis – 2021 update

The BSPED DKA SIG is happy to share the updated DKA guidelines which replace the BSPED interim guideline published in 2020, in light of the update to the NICE Guidance NG18 (December 2020) and to the UK Resuscitation Council recommendations (May 2021). [You can read them online here](#)

New and improved BSPED Paediatric DKA Calculator

The [DKA Calculator](#) has been updated in line with the [2021 BSPED DKA Guidelines](#):

- Deficit percentage for moderate DKA reduced from 7% to 5%
- 1st resus bolus volume reduced from 20mL/kg to 10mL/kg
- Upper weight limit reduced from 80kg to 75kg
- Safety limits now apply to all calculated values including bolus, deficit and maintenance volumes, and insulin rates
- Design and codebase improvements
- [Click here to view the full change log \(version 1.2.0\)](#)

[Access to the legacy version \(v1.1.10\)](#) of the DKA Calculator will be supported until April 2022.

Try it out at dka-calculator.co.uk

SAFETY NOTICE- Fludrocortisone dosing National Neonatal Formulary 8th Edition

<https://global.oup.com/academic/product/neonatal-formulary-9780198840787?cc=gb&lang=en&>

BSPED would like to make members aware of an error printed in the in the above National Neonatal Formulary 8th edition. The current edition states fludrocortisone doses in micrograms per kg rather than microgram per m². This is being addressed by the publishers and the information is being shared with the neonatal networks and with the national phamacists network.

It would be prudent for members to ensure staff in their units are aware of this and also highlight this error to referring shared care centres when fludrocortisone prescriptions are being advised.

Clinical Studies Group call for research narratives

The CSG is aiming to showcase the breadth and depth of research in paediatric endocrinology and will host research narratives from each centre on the BSPED website. If you haven't done so already, you could write a paragraph or a page (or two) on current and future perspectives of research at your centre. Please contact the CSG Chair if you would like further information or if you would like to see an example. <https://www.bsped.org.uk/research/uk-research-perspectives/>



The BSPED Clinical Studies Group (CSG) is also aiming to refresh the list of studies on the website. If you have an exciting study in paediatric endocrinology and you'd like to share information about this, please contact the BSPED office. <https://www.bsped.org.uk/research/active-clinical-studies/>

BSPED statement on Covid-19 vaccination in children aged 12 - 15 with underlying health conditions

The Joint Committee on Vaccinations and Immunisations (JCVI) has issued updated guidance on vaccination in children aged 12 to 15 years with underlying health conditions. [Read more on this](#) and find the [full statement here](#).

BSPED Online Communication Strategy

The clinical content of the website, newsletter and social media engagement falls under the remit of the Clinical Committee. A [BSPED Online Communication Strategy](#) has been formulated to increase engagement across the membership, provide a platform for guidance, advice and news and promote high quality training and professional development opportunities.



Declaration of interests for guideline endorsement

If you would like a guideline to be endorsed or supported by the BSPED, we ask that you first complete a [declaration of interests form, which can be found here](#).

***Use of and comments regarding guidelines**

BSPED guidelines have been commissioned and endorsed by the BSPED and reflect the Society's views on best practice for the majority of patients with that condition. However, each patient should be considered as an individual in the context of their condition and other medication and therefore the readers' discretion is required in the application of their use. Every effort has been made to ensure the factual accuracy of the contents but no liability can be accepted for any litigation, claims or complaints arising from the use of the guidelines.

If you have a query or comment, or would like to raise a concern regarding a BSPED guideline or any guideline on our website, please contact the [BSPED Office](#) who will ensure your message is passed to the BSPED Clinical Guidelines Officer and Clinical Committee.

Surveys

If you would like to include a survey in a BSPED newsletter to encourage responses from BSPED members, please submit it to the BSPED Office. The survey will be reviewed at the next Clinical Committee meeting and included in the newsletter if approved. Survey owners should agree to report their findings back to the Clinical Committee 6 months after the survey closes. The BSPED should be acknowledged in any output (guidelines, publications, presentations, etc) resulting from the survey and the BSPED Office informed of the output.



Submitting items to the Clinical Committee

In order to manage the full agenda of this busy committee we would request that any items that members would like to be reviewed by the Clinical Committee should be submitted to the committee through the BSPED Office in good time. Please see below the deadline dates for submission for the upcoming Clinical Committee meeting: February 2022.

Announcements

Paediatric Endocrinology Clinical Research Fellowship posts Nuffield Department of Medicine, University of Oxford

Are you interested in doing clinical research? Do you want to become a leading paediatric diabetes academic of the future?

We are looking for dynamic, enthusiastic and committed paediatric trainees who would like to undertake a fellowship leading to a PhD, to work with us at the University of Oxford, in the area of type 1 diabetes screening. General population screening for childhood type 1 diabetes is an exciting new area of research both in the UK and internationally. Fellows will be supervised by Paediatric endocrinologist Dr Rachel Besser and Adult diabetologist/immunologist and type 1 diabetes consortium lead, Professor Colin Dayan. To understand more about this area, please follow this link for a recent review article we have published: <https://pubmed.ncbi.nlm.nih.gov/34740879/>



Successful candidates would be expected to register for a higher degree at the University of Oxford during the fellowship. Applicants must have GMC registration, and be on a paediatric training programme, and want to work in childhood type 1 diabetes.

The deadline for expressions of interest is December 31st 2021. For enquiries, please contact Dr Rachel Besser: rachel.besser@ouh.nhs.uk

The Novo Nordisk UK Research Foundation 2022 Call for Applications

Applications are now invited for research and education funding in diabetes for 2022, all awards are made on a competitive basis. Applicants are preferred to be working in a patient facing role but this is not an absolute requirement. The Foundation is an independent registered charity: 1056410, AMRC member and a NIHR partner. Awards will be announced in April 2022.

Fund Awards – for nurses and allied healthcare professionals in diabetes care.

- Attendance at a national or international meeting (preference to those presenting their work) up to £1,000.
- A course of study up to £2,000.
- Clinical project up to £5,000.

[Find out more here.](#)

Closing date for the Fund Awards: 2 February 2022

CG 2284 Consultant in Paediatric Endocrinology and Diabetes

Location: **Royal Hospital for Children and Young People**

Confirmation that the above post is currently being advertised with the reference CG 2284 (Jobtrain vacancy number 81702).

Link to advert: <https://apply.jobs.scot.nhs.uk/displayjob.aspx?jobid=82044>

The closing date for application forms is: **16th January 2022.**

You can get the latest articles published in ADC straight to your inbox by signing up the e alerts and TOC. Click below to sign up and stay up to date.

Archives of Disease in Childhood

- <https://emails.bmj.com/k/Bmj/jausu/archdischild>

Education & Practice edition

- <https://emails.bmj.com/k/Bmj/jausu/edpract>

Fetal & Neonatal edition

- <https://emails.bmj.com/k/Bmj/jausu/fetalneonatal>



Meetings and courses

We have made every effort to check whether meetings have been postponed or cancelled due to Covid-19 and have updated the details below where possible. We would however recommend that you check with the website/organiser of any event you plan to attend this year.

2021-2022 Annual endocrinology and diabetes meetings

- **European Society of Endocrinology ECE 2022**: 21-24 May 2022, Milan, Italy
 - **ENDO 2022**: 11-14 June 2022, Atlanta, Georgia
 - **10th International Conference on Children's Bone Health**
2-5 July 2022 in Dublin, Ireland
<https://www.iccbh.org/>
 - **ICCBH Bone School**
29 June – 1 July 2022 in Dublin, Ireland
<https://www.iccbhboneschool.org/>
 - **14th International Conference on Osteogenesis Imperfecta**
30 August to 2 September 2022 in Sheffield, UK
<https://oi2022.org/>
-

Update in Obstetrics, Gynecology and Reproductive Medicine ~~4-5 November 2021, Barcelona~~ Postponed until 2022

Unfortunately, at this time, COVID-19 still remains prominent in the public health sphere. Therefore, as the safety and well-being of all of the Dexeus Forum's participants, faculty and staff are our highest priority, we believe it is best to postpone the congress to a later date.

The Dexeus Women's Health Foundation has decided to postpone its 45th International Forum focusing on issues in Women's Health to 2022.

The face-to-face 2022 Dexeus Forum will follow in the footsteps of the previous highly successful Forums and will update the current knowledge in Obstetrics, Gynecology and Reproductive Medicine with the key international opinion leaders in each field.

<http://dexeus.comtecmed.com/>

16th ACDC Annual Conference 2022

Next year's 2022 16th ACDC Annual Conference will be held at Conference Aston, Aston University Campus B7 4BL Birmingham on Friday, 6th May, 2022.

Please visit our website at <http://www.a-c-d-c.org/forthcoming-acdc-meetings/> to register to book your place via the Eventbrite link as tickets will be limited and on a first come first available basis- <https://www.eventbrite.co.uk/e/16th-acdc-annual-conference-tickets-162895798719>

See more Meetings and Courses on the [Other Meetings](#) page on the BSPED website.

If you have any meetings, courses or events that you'd like to add to this page, please [submit them for review here](#).

Benefactor Spotlight

The BSPED is very grateful for the support of our benefactors, without which the work of the Society would not be possible. We are pleased to introduce you to our 2021/2022 benefactors. Thank you to all of the following for their ongoing support:

Partners:



Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life, in biopharmaceuticals, developing therapies to treat cancer, multiple sclerosis, and endocrine conditions.

In endocrinology, Merck has established treatments in diabetes and growth hormone replacement, treating thousands of patients in the UK. With growth hormone therapy we are enhancing our digital tools in line with NHS Digital transformation plan and are committed to meeting patients' and healthcare professionals' evolving needs.

Merck has launched new systems and apps which work in conjunction or alongside the easypod™ injection device, to support both the patient and healthcare professional get the best from Merck therapies. New systems include: a new easypod™ Connect platform, growlink™ app and easypod™ Augment Reality (AR) App. These digital solutions are integrated to the MySupport patient support programme, available for device training and nurse-led support.



Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit [novonordisk.co.uk](https://www.novonordisk.co.uk), [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).



About Pfizer: Breakthroughs that change patients' lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

To learn more, please follow us on [Twitter](#), [Instagram](#) and like us on [Facebook](#).
<https://www.pfizerpro.co.uk/>

Gold:



Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialisation of life changing medicines.

As a leader in rare disease for more than 25 years, Alexion has developed and commercialised complement inhibitors to treat patients with complement-mediated disorders. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders. In addition, the company is developing several therapies and focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of haematology, nephrology, neurology, metabolic disorders and cardiology



Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork, innovation and integrity.

You can learn more about the business of Kyowa Kirin at:
<https://international.kyowa-kirin.com/uk/>

Silver:



Diurnal Group plc is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions. Since inception in 2004, our company mission has been clear; to address crucial unmet patient and clinical need in the endocrine field and deliver best health outcomes to improve patients' quality of life.

Our expertise and innovative research activities focus on circadian-based endocrinology. We have created a specialised pipeline of product candidates within the endocrine area, with the primary goal of improving patient outcomes and lives.

Diurnal – creating new therapies for patients with chronic hormone-related rare diseases
www.diurnal.co.uk

Bronze:



At Abbott, we believe people with diabetes should enjoy active lives, so we're focused on making breakthrough technology accessible and approachable for all. Our ground-breaking sensing technology is revolutionising how people monitor glucose and providing healthcare teams with more data to make better informed treatment decisions.

www.FreeStyleDiabetes.co.uk and www.FreeStyleLibre.co.uk



Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.

The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

For more information, please visit: www.insulet.com and www.omnipod.com/en-gb/hcp



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

For more information please visit www.sanofi.co.uk.

Sent by the BSPED Office

BSPED
c/o Bioscientifica Ltd
Starling House,
1600 Bristol Parkway North,
Bristol, BS34 8YU
bsped@endocrinology.org
Tel: 01454 642258